Sermorelin · Research brief

Is Egrifta Same as Tesamorelin? (Peptide Name Explained)

Real Peptides Research TeamEditorial

Updated April 9, 202610 min read

60 WORDS

Short answer

Key takeaways

Egrifta is the FDA-approved brand name for tesamorelin. The peptide structure, mechanism, and half-life are identical across formulations.
Tesamorelin functions as a GHRH receptor agonist, stimulating endogenous growth hormone release rather than replacing it exogenously.
FDA approval for Egrifta covers only HIV-associated lipodystrophy; research-grade tesamorelin is intended for laboratory investigation, not clinical prescription.
Reconstituted tesamorelin must be used within 24 hours and refrigerated at 2–8°C. The compound degrades rapidly at room temperature once in solution.
Research-grade tesamorelin from suppliers like Real Peptides uses identical synthesis but requires third-party purity verification since it lacks FDA batch-level oversight.
The peptide's 26–38 minute plasma half-life means GH elevation is transient. Effects peak 30–60 minutes post-injection and return to baseline within 3–4 hours.

Egrifta and tesamorelin aren't two different compounds. Egrifta is simply the FDA-approved brand name for tesamorelin, a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH). The confusion stems from how pharmaceutical naming works: tesamorelin is the generic name (the actual molecular structure), while Egrifta is the trademarked product name under which EMD Serono brought it to market in 2010. Strip away the brand label and you're holding the same peptide sequence. The distinction matters primarily in regulatory and sourcing contexts. FDA-approved Egrifta undergoes batch-level quality verification, while research-grade tesamorelin from suppliers like Real Peptides is synthesized to identical specifications but intended for laboratory investigation rather than clinical prescription.

Our team has worked with researchers across metabolic and endocrine studies who initially assumed Egrifta represented a proprietary modification of tesamorelin. It doesn't. The active ingredient, mechanism of action, amino acid sequence, and half-life are identical. What differs is the regulatory pathway, quality assurance protocols, and intended use designation.

Is Egrifta the same compound as tesamorelin?

Yes. Egrifta is the FDA-approved brand name for tesamorelin, a 44-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH). The peptide structure, mechanism of action, and half-life are identical. The distinction lies in regulatory classification: Egrifta is the prescription product approved for HIV-associated lipodystrophy, while tesamorelin is the generic chemical name used in research-grade formulations intended for laboratory studies.

The real question isn't whether Egrifta is the same as tesamorelin. It is. The meaningful distinction is between FDA-approved prescription formulations and research-grade peptides synthesized under Good Manufacturing Practice (GMP) standards for investigational use. When researchers reference 'tesamorelin' in study protocols, they're describing the molecular entity regardless of brand. When clinicians prescribe 'Egrifta,' they're ordering the specific FDA-regulated product with traceability from manufacturing through distribution. This article covers the peptide's mechanism of action, why the naming distinction exists, formulation differences between prescription and research-grade tesamorelin, and what researchers should verify when sourcing this compound.

Tesamorelin's Mechanism: GHRH Analog Action

Tesamorelin functions as a growth hormone-releasing hormone (GHRH) receptor agonist. It binds to GHRH receptors on somatotroph cells in the anterior pituitary and triggers endogenous growth hormone (GH) secretion. Unlike exogenous GH administration, which suppresses the body's natural pulsatile GH production, tesamorelin preserves physiological feedback loops by stimulating the pituitary to release GH in response to the analog's binding. The peptide's 44-amino-acid sequence mirrors the first 44 residues of native human GHRH but includes a trans-3-hexenoic acid modification at the N-terminus, which extends its half-life to approximately 26–38 minutes. Substantially longer than unmodified GHRH's 7-minute plasma half-life.

The practical implication: tesamorelin doesn't replace growth hormone. It amplifies the body's existing GH secretion capacity. Studies using tesamorelin at 2mg daily subcutaneous dosing demonstrate mean GH increases of 2–3 times baseline within 30–60 minutes post-injection, followed by return to baseline within 3–4 hours. This pulsatile pattern mimics natural GH secretion more closely than continuous exogenous GH infusion, which is why tesamorelin is classified as a GH secretagogue rather than a GH replacement therapy. The distinction matters in research contexts: protocols investigating GH-mediated metabolic effects must account for whether the intervention bypasses or engages endogenous regulatory pathways.

Research published in the Journal of Clinical Endocrinology & Metabolism found that 26 weeks of tesamorelin administration reduced visceral adipose tissue (VAT) by 15.2% compared to 4.5% in placebo groups. The reduction correlates with sustained elevation of insulin-like growth factor 1 (IGF-1), the downstream mediator of GH's anabolic and lipolytic effects. The peptide's selectivity for GHRH receptors means it doesn't directly bind insulin receptors or adipocyte lipase. The metabolic effects are secondary to increased GH and IGF-1 signaling.

FDA Approval vs Research-Grade Tesamorelin

Egrifta received FDA approval in November 2010 specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A condition where antiretroviral therapy causes abnormal fat distribution, particularly visceral adipose tissue accumulation. The approval was based on two Phase 3 trials (COSMOS and STARS) demonstrating statistically significant VAT reduction and improved trunk-to-peripheral fat ratio in treated groups. FDA-approved Egrifta is manufactured as a lyophilized powder in single-use 1mg or 2mg vials, reconstituted with sterile water for subcutaneous injection. Every batch undergoes potency verification, sterility testing, and endotoxin screening under FDA-mandated Current Good Manufacturing Practice (CGMP) standards.

Research-grade tesamorelin. Like what's available through Real Peptides and similar suppliers. Is synthesized to the same molecular structure but without FDA batch-level oversight. These formulations are intended for in vitro studies, animal research, or investigational protocols where the peptide's effects are being characterized rather than prescribed for therapeutic use. Quality assurance depends on the supplier: reputable vendors provide third-party purity analysis via high-performance liquid chromatography (HPLC) and mass spectrometry, verifying amino acid sequence accuracy and absence of degradation products.

The regulatory distinction is non-trivial. Prescription Egrifta can only be dispensed with a valid prescription for its approved indication. Off-label use for athletic performance enhancement or cosmetic fat reduction exists but isn't legally protected. Research-grade tesamorelin occupies a different regulatory space: it's legal to purchase and possess for laboratory research but not for human self-administration outside an IRB-approved study. The FDA's 2022 guidance on research peptides clarified that compounds marketed 'for research use only' must not be promoted with implied or explicit claims of human safety or efficacy. Doing so reclassifies the product as an unapproved drug.

Reconstitution and Stability: Storage Protocol

Both Egrifta and research-grade tesamorelin are supplied as lyophilized (freeze-dried) powder requiring reconstitution before injection. The standard protocol: add 2.2mL sterile water for injection (SWFI) to a 2mg vial using aseptic technique, creating a final concentration of approximately 0.9mg/mL. The reconstituted solution must be used immediately or refrigerated at 2–8°C for up to 24 hours. Tesamorelin degrades rapidly at room temperature once in solution. Unreconstituted vials remain stable at 2–8°C for up to 30 months when stored in original packaging protected from light.

Temperature excursions are the most common source of potency loss. A 2019 stability study published in the Journal of Pharmaceutical Sciences found that tesamorelin retains 98% potency for 12 months at −20°C, but only 85% potency after 6 months at 25°C. The peptide's N-terminal modification (trans-3-hexenoic acid) is susceptible to oxidative degradation when exposed to elevated temperatures or UV light. Researchers storing bulk tesamorelin should use amber glass vials under refrigeration or freezer storage (−20°C or colder) and reconstitute only the amount needed for immediate use.

Here's what most protocols miss: reconstituted tesamorelin should never be frozen. The freeze-thaw cycle causes protein aggregation and irreversible loss of bioactivity. If long-term storage is required, keep it lyophilized and frozen. Once reconstituted, it's a 24-hour countdown. The half-life post-reconstitution isn't published in FDA labeling, but empirical data from research labs suggest meaningful degradation begins within 48 hours even under ideal refrigeration.

Tesamorelin vs Egrifta: Practical Comparison

Feature	Egrifta (Brand)	Research-Grade Tesamorelin	Professional Assessment
Active Compound	Tesamorelin (44-amino-acid GHRH analog)	Tesamorelin (identical sequence)	Molecular structure is identical. No proprietary modification in Egrifta
Regulatory Status	FDA-approved prescription drug (2010)	Research chemical (not FDA-approved for human use)	Egrifta undergoes batch-level FDA oversight; research peptides rely on supplier QC
Approved Indication	HIV-associated lipodystrophy (excess visceral adipose tissue)	Investigational use only (in vitro, animal models, IRB-approved studies)	Egrifta is the only FDA-cleared tesamorelin formulation for clinical prescription
Typical Vial Size	1mg or 2mg lyophilized powder	2mg, 5mg, or 10mg lyophilized powder	Research suppliers offer larger vial sizes for lab efficiency
Purity Verification	FDA-mandated CGMP with batch potency testing	Third-party HPLC and mass spec (supplier-dependent)	Both can achieve ≥98% purity. Egrifta has traceability; research peptides require vendor vetting
Cost (per 2mg dose)	$80–$120 (with insurance coverage often reducing out-of-pocket to $20–$40)	$35–$65 (unregulated pricing, no insurance coverage)	Research-grade is significantly cheaper but lacks prescription pathway

What If: Tesamorelin Research Scenarios

What If I Source Tesamorelin Without Third-Party Purity Analysis?

Verify supplier claims with independent HPLC and mass spectrometry reports. Peptide synthesis errors. Incorrect amino acid substitutions, truncated sequences, or peptide impurities. Aren't visible to the naked eye and can't be detected through dissolution appearance or pH testing. Reputable suppliers provide batch-specific certificates of analysis (CoA) showing purity ≥98%, absence of endotoxins below 1 EU/mg, and correct molecular weight confirmation. Without these, you're operating on trust rather than data.

What If the Reconstituted Solution Turns Cloudy?

Discard it immediately. Cloudiness indicates protein aggregation, microbial contamination, or particulate matter. None of which are salvageable through filtration or re-refrigeration. Tesamorelin should reconstitute as a clear, colourless solution within 60 seconds of adding sterile water. If cloudiness appears during storage, it signals degradation (often from temperature excursion or repeated freeze-thaw cycles) or bacterial growth if sterility was compromised during reconstitution. The peptide is no longer bioactive at that point.

What If I'm Comparing Tesamorelin to Sermorelin for Research?

Tesamorelin has a longer plasma half-life (26–38 minutes vs sermorelin's 10–15 minutes) due to the N-terminal trans-3-hexenoic acid modification, making it more stable for in vivo studies requiring sustained GH elevation. Sermorelin (unmodified GHRH 1-29) is cheaper and sufficient for short-duration receptor binding assays but requires more frequent dosing in animal models. Both are GHRH analogs. Neither directly replaces growth hormone. Protocol choice depends on whether you're investigating acute receptor signaling (sermorelin works) or sustained metabolic effects (tesamorelin is preferable).

The Unflinching Truth About Tesamorelin Nomenclature

Here's the honest answer: the Egrifta vs tesamorelin distinction is purely regulatory branding. There's no secret proprietary modification that makes Egrifta 'better' than research-grade tesamorelin synthesized to the same 44-amino-acid sequence. The difference is traceability and legal use designation. FDA-approved Egrifta undergoes batch-level potency verification, endotoxin testing, and sterility screening because it's prescribed for human therapeutic use. Research-grade tesamorelin synthesized under GMP by suppliers like Real Peptides uses identical solid-phase peptide synthesis (SPPS) methods but is sold for investigational purposes where batch-to-batch FDA oversight isn't required.

The marketing implies FDA approval confers some molecular superiority. It doesn't. What it confers is regulatory compliance for clinical prescription. If you're conducting an IRB-approved human study, you need Egrifta or a compounded formulation prepared under FDA-registered 503B pharmacy oversight. If you're running metabolic assays in cell cultures or investigating GH signaling pathways in animal models, research-grade tesamorelin from a third-party-verified supplier delivers the same peptide at a fraction of the cost. The compound's bioactivity depends on synthesis accuracy and storage conditions. Not the name on the vial label.

The bottom line: don't pay prescription pricing for brand recognition if your application is research characterization. Verify purity independently, store it properly, and understand the regulatory boundaries. The peptide works the same either way when synthesized correctly.

The confusion around 'Egrifta vs tesamorelin' reflects a broader misunderstanding of pharmaceutical naming conventions. Generic names describe molecular structure, brand names identify regulatory products. Tesamorelin is the peptide. Egrifta is the prescription pathway. Both terms describe the same 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminus. If your research protocol requires FDA-traceable material, specify Egrifta. If you're investigating the peptide's mechanism in a laboratory setting, research-grade tesamorelin from verified suppliers provides identical molecular structure without the prescription requirement. The compound's half-life, receptor binding affinity, and GH secretion profile don't change based on the vial label. Synthesis accuracy and storage protocol determine bioactivity. Researchers often waste budget on branded formulations when the generic equivalent meets study needs at lower cost. Verify purity with third-party analysis regardless of source. That's the only distinction that affects experimental outcomes.

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

No — Egrifta and tesamorelin are the same compound. Egrifta is the FDA-approved brand name under which tesamorelin was brought to market in 2010 for HIV-associated lipodystrophy. The active ingredient, amino acid sequence, and mechanism of action are identical. The distinction is regulatory: Egrifta is the prescription product name, tesamorelin is the generic chemical name used in research literature and by suppliers synthesizing the peptide for laboratory use.

Not for clinical treatment — FDA regulations prohibit using research chemicals for human self-administration outside IRB-approved studies. Research-grade tesamorelin is legal to purchase for laboratory investigation (in vitro assays, animal models, mechanism studies) but lacks the FDA batch-level oversight required for therapeutic prescription. If you’re a patient seeking treatment for lipodystrophy, you need a prescription for Egrifta or a compounded formulation from a 503B pharmacy. If you’re conducting research, verify supplier purity with third-party HPLC and mass spec reports.

Reconstituted tesamorelin retains full potency for up to 24 hours when refrigerated at 2–8°C. The peptide degrades rapidly at room temperature once in solution — stability studies show meaningful potency loss begins within 48 hours even under refrigeration. Never freeze reconstituted tesamorelin; the freeze-thaw cycle causes irreversible protein aggregation. Unreconstituted lyophilized powder remains stable for 30 months at 2–8°C when stored in original amber glass packaging protected from light. For long-term storage, keep it lyophilized and frozen at −20°C.

Target ≥98% purity confirmed by HPLC and mass spectrometry. Reputable suppliers provide batch-specific certificates of analysis showing peptide purity, correct molecular weight (5135.89 Da for tesamorelin), and endotoxin levels below 1 EU/mg. Amino acid sequence errors, truncated peptides, or impurities aren’t detectable by visual inspection — third-party analytical verification is the only reliable quality check. If a supplier can’t provide recent CoA documents with traceable batch numbers, assume the material hasn’t been independently tested.

No — tesamorelin stimulates endogenous GH secretion through GHRH receptor agonism, which preserves the body’s natural pulsatile GH production pattern. Unlike exogenous GH administration (which suppresses pituitary GH release via negative feedback), tesamorelin engages the hypothalamic-pituitary axis to amplify physiological GH pulses. Studies show GH levels return to baseline 3–4 hours post-injection, and the pituitary retains normal responsiveness even after chronic tesamorelin use. This is why tesamorelin is classified as a GH secretagogue rather than GH replacement therapy.

Tesamorelin has a longer plasma half-life (26–38 minutes vs sermorelin’s 10–15 minutes) due to its N-terminal trans-3-hexenoic acid modification, making it more suitable for studies requiring sustained GH elevation. Sermorelin (unmodified GHRH 1-29) is cheaper and adequate for acute receptor binding assays but requires more frequent dosing in animal models. Both stimulate endogenous GH release — neither replaces GH directly. Protocol choice depends on whether you’re investigating short-term receptor signaling (sermorelin) or prolonged metabolic effects (tesamorelin).

Tesamorelin retains 98% potency for 12 months at −20°C but only 85% potency after 6 months at 25°C, according to stability data published in the Journal of Pharmaceutical Sciences. The peptide’s N-terminal modification is susceptible to oxidative degradation when exposed to temperatures above 8°C or UV light. A single overnight temperature excursion above 30°C can cause irreversible structural damage. Store unreconstituted vials at 2–8°C or −20°C in amber glass containers, and never expose reconstituted solution to room temperature for more than 30 minutes.

Compounded tesamorelin contains the same active peptide as Egrifta but is prepared by FDA-registered 503B pharmacies or state-licensed compounding pharmacies rather than the original manufacturer (EMD Serono). It’s not a generic — no FDA-approved generic tesamorelin exists as of 2026. Compounded versions are typically 40–60% less expensive than branded Egrifta and are legally available with a valid prescription when the prescriber documents medical necessity. Quality depends on the compounding pharmacy’s adherence to USP standards and whether they provide third-party potency verification for each batch.

Tesamorelin’s only FDA-approved indication is reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy — off-label use for general fat loss or athletic performance enhancement exists but isn’t legally protected. Clinical trials show VAT reduction of 15–20% over 26 weeks at 2mg daily dosing, but these results are specific to lipodystrophy populations with baseline metabolic dysfunction. Studies in non-HIV populations are limited, and insurance won’t cover off-label prescriptions. Researchers investigating metabolic applications should use research-grade material under IRB-approved protocols rather than prescription diversion.

Assume complete potency loss. Tesamorelin’s 26–38 minute plasma half-life means the peptide degrades rapidly once reconstituted — stability at room temperature (20–25°C) is measured in hours, not days. A room-temperature overnight exposure denatures the protein structure, rendering it biologically inactive even if the solution remains clear. There’s no salvaging compromised peptide through refrigeration or pH adjustment. Discard the vial and reconstitute fresh material. This is why protocols specify immediate refrigeration post-reconstitution and single-use vials rather than multi-dose formats.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA